Rahul Dave
Neurology · Fairfax, VANPI 1700101698
Payments from drug & device makers
Across 913 payments — averaging $1116.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$406K
- TG Therapeutics, Inc.$147K
- EMD Serono, Inc.$137K
- AstraZeneca$88K
- Sanofi$77K
- Biogen$51K
- plus $114K from 30 others
Across 14 payments — averaging $333.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$3K
- Sanofi US Services Inc.$2K
What the payments were for
- Consulting fees$66,12212%
- Speaking & faculty fees$403,16375%
- Travel & lodging$38,0377%
- Food & beverage$32,2526%
- Education$4320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 113 | $406,440 |
| TG Therapeutics, Inc. | 91 | $147,157 |
| EMD Serono, Inc. | 125 | $136,584 |
| AstraZeneca(2 entities) | 93 | $87,954 |
| Sanofi | 46 | $76,790 |
| Biogen | 61 | $50,605 |
| Amgen(2 entities) | 91 | $44,558 |
| Genentech USA, Inc. | 58 | $23,324 |
| E.r. Squibb & Sons, L.L.C. | 13 | $19,336 |
| Bristol Myers Squibb | 55 | $9,930 |
| Argenx US, Inc. | 21 | $7,418 |
| UCB, Inc. | 14 | $5,584 |
| AbbVie(2 entities) | 64 | $1,034 |
| Teva Pharmaceuticals USA, Inc. | 5 | $452 |
| Lilly USA, LLC | 10 | $277 |
| Genentech, Inc. | 4 | $265 |
| ANI Pharmaceuticals, Inc. | 2 | $260 |
| Avanir Pharmaceuticals, Inc. | 7 | $201 |
| Sunovion Pharmaceuticals Inc. | 6 | $192 |
| Supernus Pharmaceuticals, Inc. | 8 | $191 |
| Lundbeck LLC | 5 | $141 |
| SK Life Science, Inc. | 3 | $71 |
| Sanofi-aventis U.S. LLC | 2 | $67 |
| Sandoz | 1 | $64 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $46 |
| Bausch Health US, LLC | 2 | $38 |
| Acorda Therapeutics, Inc | 2 | $36 |
| Pfizer | 1 | $33 |
| Biohaven Pharmaceuticals, Inc. | 1 | $28 |
| Eisai Inc. | 1 | $25 |
| Harmony Biosciences LLC | 1 | $23 |
| Scilex Pharmaceuticals Inc. | 1 | $22 |
| Neurelis, Inc. | 1 | $16 |
| Medtronic | 1 | $15 |
| Mallinckrodt Enterprises LLC | 1 | $15 |
| Ironshore Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,019,204 in reported general payments places this provider in the 95th percentile of 474 neurology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 233 | $2,072,110 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 52 | $1,208,059 |
| MavencladCladribine | 15 | $1,038,710 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 50 | $502,971 |
| EnspryngSatralizumab-Mwge | 12 | $210,233 |
| AubagioTeriflunomide | 20 | $200,488 |
| Teriflunomide | 52 | $140,406 |
| Nurtec OdtRimegepant Sulfate | 16 | $31,250 |
| Dimethyl Fumarate | 29 | $29,371 |
| MyrbetriqMirabegron | 15 | $18,976 |
| Mycophenolic AcidMycophenolate Sodium | 18 | $10,283 |
| Atomoxetine Hcl | 49 | $9,124 |
| Dalfampridine ErDalfampridine | 29 | $8,792 |
| Modafinil | 39 | $8,117 |
| Pregabalin | 95 | $5,726 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| EMD Serono, Inc.Mavenclad | $136,584 | $1,038,71015 claims |
| Genentech USA, Inc.Enspryng | $23,324 | $210,23312 claims |
| SanofiAubagio | $76,790 | $200,48820 claims |
| PfizerNurtec Odt | $33 | $31,25016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 474 neurology providers in Virginia.
Other neurology in Fairfax
- John RothrockFairfax$504K
- James SimsarianFairfax$173K
- Laura CinskiFairfax$124K
- Abigail LawlerFairfax$107K
- Michelle BetzVirginia Beach$3.3M
- Daniel CohenNorfolk$2.9M
- Heidi CraytonVienna$2.5M
- Ramsey FalconerAlexandria$2.4M
- Robert ShinCharlottesville$2.2M
- Simon FishmanAlexandria$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.